Low-Grade Glioma in Children and Adolescents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F24%3A10497337" target="_blank" >RIV/00064203:_____/24:10497337 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/24:10497337

Výsledek na webu

<a href="https://doi.org/10.1007/978-3-031-62017-1_9" target="_blank" >https://doi.org/10.1007/978-3-031-62017-1_9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/978-3-031-62017-1_9" target="_blank" >10.1007/978-3-031-62017-1_9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Low-Grade Glioma in Children and Adolescents

Popis výsledku v původním jazyce

Low-grade gliomas are the most common CNS tumours in children and adolescents. Different from their adult counterparts, Paediatric Low-Grade Gliomas (PLGG) have high survival rates with very few patients dying from disease. During the last 15 years, extraordinary biology findings have occurred in these tumours leading to a new WHO 2021 classification based on molecular alterations. A complete pathology-molecular-methylation study is now recommended in these tumours for a precise diagnosis and molecular targets. Surgery is still the main treatment for those resectable tumours. For non-resectable, chemotherapy and radiotherapy (in selected cases) are used. In the last years, targeted therapy is gaining visibility with good results and reasonable toxicity. Long-term quality of life of the patients remains an important aim when choosing the best treatment for these patients.

Název v anglickém jazyce

Low-Grade Glioma in Children and Adolescents

Popis výsledku anglicky

Low-grade gliomas are the most common CNS tumours in children and adolescents. Different from their adult counterparts, Paediatric Low-Grade Gliomas (PLGG) have high survival rates with very few patients dying from disease. During the last 15 years, extraordinary biology findings have occurred in these tumours leading to a new WHO 2021 classification based on molecular alterations. A complete pathology-molecular-methylation study is now recommended in these tumours for a precise diagnosis and molecular targets. Surgery is still the main treatment for those resectable tumours. For non-resectable, chemotherapy and radiotherapy (in selected cases) are used. In the last years, targeted therapy is gaining visibility with good results and reasonable toxicity. Long-term quality of life of the patients remains an important aim when choosing the best treatment for these patients.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Pediatric Neuro-oncology

ISBN

978-3-031-62016-4

Počet stran výsledku

13

Strana od-do

143-155

Počet stran knihy

570

Název nakladatele

Springer

Místo vydání

Cham

Kód UT WoS kapitoly

—